目錄:MedChemExpress LLC>>生化試劑>> Flumatinib | MCE
CAS | 895519-90-1 | 純度 | 99.94% |
---|---|---|---|
分子量 | 562.59 | 分子式 | C??H??F?N?O |
供貨周期 | 現貨 | 規格 | 5 mg |
貨號 | HY-13904 | 應用領域 | 醫療衛生,化工,生物產業,制藥 |
MCE 的所有產品僅用作科學研究或藥證申報,我們不為任何個人用途提供產品和服務。
CAS No. : 895519-90-1
產品活性:Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.
研究領域:Protein Tyrosine Kinase/RTK
作用靶點:Bcr-Abl | c-Kit | PDGFR
In Vitro: Flumatinib (HH-GV-678) can predominantly inhibit the autophosphorylation of Bcr-Abl in K562 cell. In higher concentration, Flumatinib can inhibit the phosphorylation of c-Kit in Mo7e cell and the phosphorylation of PDGFR in Swiss3T3 cell, however, Flumatinib has no or little effect on other tyrosine kinase including EGFR, KDR, c-Src and HER2 [1]. Flumatinib (HHGV678) effectively overcame the drug resistance of certain KIT mutants with activation loop mutations (i.e., D820G, N822K, Y823D, and A829P) [2].
相關產品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Kinase Inhibitor Library | Protein Tyrosine Kinase Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Drug Repurposing Compound Library | Reprogramming Compound Library | NMPA-Approved Drug Library | Cytoskeleton Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Alzheimer's Disease Compound Library | Anti-Blood Cancer Compound Library | Anti-Parkinson's Disease Compound Library | Neurodegenerative Disease-related Compound Library | Angiogenesis-Related Compound Library | Anti-Liver Cancer Compound Library | FDA-Approved Anticancer Drug Library | Anti-Pulmonary Fibrosis Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | SNIPER(ABL)-013 | Sennoside B | AT9283 | Bafetinib | Flumatinib mesylate | Multi-kinase-IN-2 | PP58 | c-Kit-IN-5-1 | CT52923 | Olverembatinib | Pexidartinib | ENMD-2076 Tartrate | GNF-2 | AZD2932 | Toceranib phosphate | BCR-ABL-IN-6 | Ponatinib hydrochloride | GNF-5 | Famitinib malate | AC710 Mesylate | Hypothemycin | Nintedanib | Motesanib Diphosphate | Vamotinib | Tandutinib | Telatinib mesylate | CT-721 | Tyrphostin AG1433 | Masitinib | Nintedanib-13C,d3
熱門產品線:重組蛋白 | 化合物庫 | 天然產物 | 熒光染料 | PROTAC | 同位素標記物 | 寡核苷酸 | 抗體 | 點擊化學
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種*僅有化合物庫,我們致力于為*科研客戶提供前沿的高品質小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領;
• 產品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產品,廣泛應用于新藥研發、生命科學等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學分析檢測分析,藥物篩選等專業技術服務;
• 設有專業的實驗中心和嚴格的質控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告,確保產品的高純度、高品質;
• 產品的生物活性多經各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業團隊跟蹤最新的制藥及生命科學研究進展,為您提供*新的活性化合物;
• 與世界各大制藥公司及著名科研機構建立了長期的合作。